Holen Sie sich die Stockscreener-App
16.13
1.32%
-0.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$16.32
Offen:
$16.25
24-Stunden-Volumen:
3.91M
Relative Volume:
0.37
Marktkapitalisierung:
$18.79B
Einnahmen:
$14.57B
Nettoeinkommen (Verlust:
$-296.50M
KGV:
-62.28
EPS:
-0.259
Netto-Cashflow:
$1.64B
1W Leistung:
-0.59%
1M Leistung:
-2.28%
6M Leistung:
+40.53%
1J Leistung:
+79.14%
1-Tages-Spanne:
$16.01
$16.42
1-Wochen-Bereich:
$15.70
$16.63
52-Wochen-Spanne:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.14 | 19.01B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.075 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.85 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.20 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.59 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris launches €650M 4.250% senior notes due 2033 offering - TradingView
Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033 - Stock Titan
Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS) - simplywall.st
Viatris Inc. (VTRS) Stock Analysis: Navigating Growth Prospects with an 8.09% Potential Upside - DirectorsTalk Interviews
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story - Yahoo Finance
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
[424B5] Viatris Inc Prospectus Supplement (Debt Securities) - Stock Titan
A Look at Viatris Inc (VTRS) After 3.4% Gain -- GF Value $11.01 vs Price $16.31 - GuruFocus
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.70% Potential Upside with a Strong Dividend Yield - DirectorsTalk Interviews
Viatris (VTRS) Holds Steady Near Support Amid Flat Trading SessionRSI Overbought Alerts - newsline.com
Liquidity Mapping Around (VTRS) Price Events - Stock Traders Daily
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Investors brace for Viatris earnings as CFO departure looms By Investing.com - Investing.com Nigeria
Here's Why Viatris (VTRS) is a Strong Value Stock - Yahoo Finance
Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - marketscreener.com
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring An 11% Potential Upside Amid Mixed Metrics - DirectorsTalk Interviews
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy? - simplywall.st
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Top Brass Sued by Investor Over India Facility Problems - Bloomberg Law News
Argus Raises Viatris Price Target to $18 From $15 - Moomoo
Why (VTRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Analyst Report Highlights Viatris Inc’s Strategic Positioning Amid Generic Drug CompetitionLow Estimate Range - newsline.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS) Under Pressure: Support Levels Tested After 1.5% DeclineVolatility Smile - newsline.com
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
Viatris Inc. (VTRS) Stock Analysis: Investor Outlook on a Healthcare Giant with an 8.44% Upside Potential - DirectorsTalk Interviews
Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam - Yahoo Finance
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders - simplywall.st
Viatris Inc.: - marketscreener.com
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Viatris (VTRS) price target increased by 10.47% to 17.48 - MSN
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
VTRS Maintains Overweight Rating -- Price Target Raised to $22 - GuruFocus
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - Yahoo! Finance Canada
Viatris CFO leaving Canonsburg pharma giant - MSN
Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating - Moomoo
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - Sahm
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Me - GuruFocus
TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viatris Inc-Aktie (VTRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Campbell Paul | See Remarks |
Mar 23 '26 |
Sale |
13.28 |
21,350 |
283,539 |
366,288 |
0.66%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):